Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
|
By LabMedica International staff writers Posted on 31 Jan 2019 |

Image: The Atellica Solution series of immunoassay and chemistry analyzers (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) showcased its wide portfolio of products and services in its core areas of laboratory diagnostics and molecular medicine at MedLab Middle East 2019. MedLab is the only medical laboratory industry event that offers manufacturers the opportunity to meet a diverse audience of buyers. From distributors to senior end-users, the 2019 edition welcomed over 19,610 medical lab and trade professionals in search of the latest innovations.
At MedLab Middle East 2019, Siemens highlighted its Atellica Solution series of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The company demonstrated how the Atellica Solution delivers even more control and simplicity for labs with revolutionary sample-management possibilities. The company also promoted its Atellica Solution Assays having of an expanding menu of over 175 assays powered by proven detection technologies. Also on display at the event was Siemens’ Aptio Automation, the total lab automation leader to optimize clinical operations.
Additionally, Siemens highlighted its wide range of assays, including the Atellica IM and ADVIA Centaur high-sensitivity troponin I assay which provide fast, accurate, actionable troponin I results to aid in the diagnosis of acute MI; the Atellica IM and ADVIA Centaur enhanced liver fibrosis test, a minimally invasive blood test with results that correlate to the level of liver fibrosis severity assessed by liver biopsy; the Atellica IM and ADVIA Centaur B·R·A·H·M·S Procalcitonin (PCT) assay which helps achieve earlier sepsis diagnosis and risk assessment to help improve patient outcomes with high low-end sensitivity; and the Atellica IM and ADVIA Centaur vitamin D total assay which helps evaluate the total amount of 25-hydroxy-vitamin D (both D2 and D3) in the blood to provide patients with accurate results, regardless of level and whether or not they are supplemented over-the-counter or by prescription.
Siemens also highlighted its range of point-of-care analyzers, including the epoc blood analysis system which offers complete blood gas and basic metabolic panel with hematocrit and lactate on a single room temperature-stable test card; the Xprecia Stride coagulation analyzer for PT/INR testing that provides high usability and lab-accurate results at the point-of-care; and the Atellica 1500 automated urinalysis system which combines fully automated urine sediment and chemistry analyzers into one streamlined system.
In the field of molecular diagnostics, Siemens demonstrated the Fast Track cycler for molecular testing that uses magnetic induction technology for robust and reliable results, and Syndromic real-time PCR multiplexing assays, one of the largest ranges of syndromically grouped real-time PCR multiplex assays covering the major infectious-disease groups.
Siemens also presented its digital healthcare solutions, including the Atellica Process Manager to operationalize processes with centralized oversight and advanced analytics; Atellica Data Manager to operationalize lab data with open, scalable test-, QC-, and result-management software; the Atellica Inventory Manager to analyze and automate inventory to reduce costs and save time; the POCcelerator Data Management System which is an open POC Informatics solution that can aggregate data from 180+ device models available from more than 40 different vendors; and the FastFinder Software, a fully automated real-time PCR interpretation platform that is compatible with select kits from Fast Track Diagnostics.
At MedLab Middle East 2019, Siemens highlighted its Atellica Solution series of flexible, scalable, automation-ready immunoassay and chemistry analyzers. The company demonstrated how the Atellica Solution delivers even more control and simplicity for labs with revolutionary sample-management possibilities. The company also promoted its Atellica Solution Assays having of an expanding menu of over 175 assays powered by proven detection technologies. Also on display at the event was Siemens’ Aptio Automation, the total lab automation leader to optimize clinical operations.
Additionally, Siemens highlighted its wide range of assays, including the Atellica IM and ADVIA Centaur high-sensitivity troponin I assay which provide fast, accurate, actionable troponin I results to aid in the diagnosis of acute MI; the Atellica IM and ADVIA Centaur enhanced liver fibrosis test, a minimally invasive blood test with results that correlate to the level of liver fibrosis severity assessed by liver biopsy; the Atellica IM and ADVIA Centaur B·R·A·H·M·S Procalcitonin (PCT) assay which helps achieve earlier sepsis diagnosis and risk assessment to help improve patient outcomes with high low-end sensitivity; and the Atellica IM and ADVIA Centaur vitamin D total assay which helps evaluate the total amount of 25-hydroxy-vitamin D (both D2 and D3) in the blood to provide patients with accurate results, regardless of level and whether or not they are supplemented over-the-counter or by prescription.
Siemens also highlighted its range of point-of-care analyzers, including the epoc blood analysis system which offers complete blood gas and basic metabolic panel with hematocrit and lactate on a single room temperature-stable test card; the Xprecia Stride coagulation analyzer for PT/INR testing that provides high usability and lab-accurate results at the point-of-care; and the Atellica 1500 automated urinalysis system which combines fully automated urine sediment and chemistry analyzers into one streamlined system.
In the field of molecular diagnostics, Siemens demonstrated the Fast Track cycler for molecular testing that uses magnetic induction technology for robust and reliable results, and Syndromic real-time PCR multiplexing assays, one of the largest ranges of syndromically grouped real-time PCR multiplex assays covering the major infectious-disease groups.
Siemens also presented its digital healthcare solutions, including the Atellica Process Manager to operationalize processes with centralized oversight and advanced analytics; Atellica Data Manager to operationalize lab data with open, scalable test-, QC-, and result-management software; the Atellica Inventory Manager to analyze and automate inventory to reduce costs and save time; the POCcelerator Data Management System which is an open POC Informatics solution that can aggregate data from 180+ device models available from more than 40 different vendors; and the FastFinder Software, a fully automated real-time PCR interpretation platform that is compatible with select kits from Fast Track Diagnostics.
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
- Mindray Displays New Generation Benchtop Cellular Analysis Line
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- BioSystems Highlights New iFOB Integral System at MedLab 2019
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more









